je.st
news
Tag: therapeutics
GVK Biosciences And Onconova Therapeutics Establish Novel Joint Development Partnership To Advance New Drugs For Cancer
2013-01-09 09:00:00| drugdiscoveryonline News Articles
GVK BIO, Asia’s leading Contract Research and Development organization and Onconova Therapeutics, a U.S. based biopharmaceutical company primarily focused on discovery and development of novel small molecules for Oncology, recently announced that they have entered into a novel joint partnership to develop new drugs for Cancer
Tags: development
advance
partnership
cancer
sparkV10 Chosen to Facilitate the Hit Optimization Process in ProMining Therapeutics
2013-01-09 06:00:00| Industrial Newsroom - All News for Today
Welwyn Garden City, UK - Cresset Group, innovative provider of chemistry software and services, announces that ProMining Therapeutics Ltd has chosen to license sparkV10 for assistance in its hit-to-lead optimization efforts. sparkV10 is Cresset's desktop bioisostere software tool which is used by medicinal and computational chemists for drug design. "sparkV10 is an exciting and powerful way of generating novel and diverse structures. We are delighted that ProMining, an early-stage ...This story is related to the following:ServicesScientific Software | Medical & Health Care Software | Desktop Publishing Software | Chemistry Analyzers
Tags: process
hit
chosen
facilitate
Alnylam Provides Key 2013 - 2014 Goals for RNAi Therapeutics Pipeline
2013-01-07 02:51:48| Biotech - Topix.net
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today its key "Alnylam 5x15" pipeline and partner program goals for 2013 through 2014.
Tags: key
goals
pipeline
therapeutics
Eisai And UCL Form Major Drug Discovery Alliance To Develop New Therapeutics For Neurological Diseases
2013-01-02 03:58:52| drugdiscoveryonline Home Page
UCL and the Japanese pharmaceutical company Eisai, today announce the agreement to establish a major drug discovery and development collaboration
Sites : [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33]